PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsQuinidine gluconate
Quinidine gluconate
Cardioquin, Nuedexta, Quinidine (quinidine gluconate) is a small molecule pharmaceutical. Quinidine gluconate was first approved as Quinaglute on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, and cardiac arrhythmias in the USA. It has been approved in Europe to treat neurobehavioral manifestations.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
behavior and behavior mechanismsD001520
Trade Name
FDA
EMA
Quinidine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
quinidine gluconateANDA2024-08-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
atrial flutterEFO_0003911D001282
cardiac arrhythmiasEFO_0004269D001145I49.9
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Dextromethorphan Hydrobromide / Quinidine Sulfate, Nuedexta, Avanir Pharms
76592822026-08-13U-1093
82274842023-07-17U-1093
ATC Codes
C: Cardiovascular system drugs
C01: Cardiac therapy drugs
C01B: Antiarrhythmics, class i and iii
C01BA: Antiarrhythmics, class ia
C01BA01: Quinidine
C01BA51: Quinidine, combinations excl. psycholeptics
C01BA71: Quinidine, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F0316119
DementiaD003704EFO_0003862F036118
Atrial fibrillationD001281EFO_0000275I48.013127
Pseudobulbar palsyD020828EFO_1001131134
Brain injuriesD001930S06.91113
Traumatic brain injuriesD000070642S06112
StrokeD020521EFO_0000712I63.911
Metabolic clearance rateD00865711
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Psychomotor agitationD011595268
Cardiac arrhythmiasD001145EFO_0004269I49.91426
Amyotrophic lateral sclerosisD000690EFO_0000253G12.211224
Motor neuron diseaseD016472EFO_0003782G12.21213
SclerosisD012598213
Cardiovascular diseasesD002318EFO_0000319I9833
Heart diseasesD006331EFO_0003777I51.933
Ventricular fibrillationD014693EFO_0004287I49.01123
SyndromeD0135771213
Brugada syndromeD053840Orphanet_130I49.81213
Show 17 more
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1313
Drug interactionsD00434722
Respiratory syncytial virus infectionsD018357EFO_100141322
Hepatitis bD00650911
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
Fatty liverD005234EFO_000393411
ConstipationD003248K59.011
Covid-19D000086382U07.111
Liver diseasesD008107EFO_0001421K70-K7711
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnemiaD000740EFO_0004272D64.911
Vascular dementiaD015140F0111
HypoxiaD000860R09.0211
Lewy body diseaseD020961EFO_0006792G31.8311
Neurodegenerative diseasesD019636EFO_0005772G31.911
HyperhomocysteinemiaD02013811
Vitamin b 12 deficiencyD014806EFO_0000734E53.811
TauopathiesD02480111
Frontotemporal dementiaD057180G31.011
Tdp-43 proteinopathiesD05717711
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameQuinidine gluconate
INN
Description
Quinidine is a cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy. It has a role as an alpha-adrenergic antagonist, an antimalarial, an anti-arrhythmia drug, a sodium channel blocker, a muscarinic antagonist, a potassium channel blocker, a P450 inhibitor, an EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor, an EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor and a drug allergen. It derives from a hydride of a cinchonan.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Identifiers
PDB
CAS-ID56-54-2
RxCUI9068
ChEMBL IDCHEMBL1200437
ChEBI ID27502
PubChem CID441074
DrugBankDB00908
UNII ID
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 374 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
5,755 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use